<code id='2F3780C0E2'></code><style id='2F3780C0E2'></style>
    • <acronym id='2F3780C0E2'></acronym>
      <center id='2F3780C0E2'><center id='2F3780C0E2'><tfoot id='2F3780C0E2'></tfoot></center><abbr id='2F3780C0E2'><dir id='2F3780C0E2'><tfoot id='2F3780C0E2'></tfoot><noframes id='2F3780C0E2'>

    • <optgroup id='2F3780C0E2'><strike id='2F3780C0E2'><sup id='2F3780C0E2'></sup></strike><code id='2F3780C0E2'></code></optgroup>
        1. <b id='2F3780C0E2'><label id='2F3780C0E2'><select id='2F3780C0E2'><dt id='2F3780C0E2'><span id='2F3780C0E2'></span></dt></select></label></b><u id='2F3780C0E2'></u>
          <i id='2F3780C0E2'><strike id='2F3780C0E2'><tt id='2F3780C0E2'><pre id='2F3780C0E2'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:entertainment    Page View:4829
          STAT

          What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how do you pronounce “Bayer”?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the search for ALS treatments, and the polarizing process of saying words in biotech.

          advertisement

          For more on what we cover, here’s the latest from the Summit; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          ARCH Venture Partners is raising $3 billion for a life sciences fund
          ARCH Venture Partners is raising $3 billion for a life sciences fund

          AdobeARCHVenturePartners,oneofthetopinvestorsinthebiotechecosystem,israising$3billionforanewfund.The

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          A $475,000 price tag for a new cancer drug: crazy or meh?

          AlexHogan/STATForgetMcGregor-Mayweather.ThebiotechworldhasbeenwaitingformonthstohearaboutNovartis’s